secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2025-01-02T23:59:59+00:00
Accession:  0001140361-25-000073
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics appoints Eduardo Rene Salas to Board of Directors
----------------------------------------------------------------

- Appointed Eduardo Rene Salas as Class I director, term expiring at 2026 annual meeting.
- Salas is former EY audit partner (2002-2019) and former CFO of Wellstat Therapeutics (2020-2022).
- He currently serves on audit committee of Intra-Cellular Therapies (since 2022).
- He will receive initial grant of options to purchase 20,011 shares of common stock.
- No material transactions or arrangements in connection with appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125000073/0001140361-25-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036125000073/ef20040947_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer